Rita Morgan
Family · Zephyrhills, FLNPI 1043547748
Payments from drug & device makers
Across 293 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$700
- Almatica Pharma LLC$692
- AbbVie$638
- Otsuka America Pharmaceutical, Inc.$540
- Teva Pharmaceuticals USA, Inc.$450
- plus $2K from 14 others
What the payments were for
- Food & beverage$5,54597%
- Education$1503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 34 | $1,106 |
| Alkermes, Inc. | 35 | $700 |
| Almatica Pharma LLC | 37 | $692 |
| AbbVie(2 entities) | 56 | $638 |
| Otsuka America Pharmaceutical, Inc. | 29 | $540 |
| Teva Pharmaceuticals USA, Inc. | 35 | $450 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $439 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $343 |
| Harmony Biosciences LLC | 4 | $212 |
| Lundbeck LLC | 8 | $156 |
| Corium, LLC | 6 | $125 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $59 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Johnson & Johnson | 1 | $33 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$373
How this compares
$5,695 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 21 | $129,764 |
| AustedoDeutetrabenazine | 12 | $98,534 |
| VraylarCariprazine Hcl | 47 | $69,963 |
| RexultiBrexpiprazole | 19 | $41,415 |
| CaplytaLumateperone Tosylate | 23 | $37,321 |
| TrintellixVortioxetine Hydrobromide | 28 | $21,316 |
| Loreev XrLorazepam | 25 | $10,879 |
| Lurasidone Hcl | 71 | $8,236 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 139 | $7,286 |
| QuviviqDaridorexant Hcl | 12 | $5,700 |
| Bupropion XlBupropion Hcl | 207 | $4,364 |
| Duloxetine Hcl | 149 | $4,221 |
| Trazodone Hcl | 203 | $2,955 |
| Aripiprazole | 106 | $2,929 |
| Quetiapine Fumarate | 140 | $2,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $450 | $228,29833 claims |
| AbbVieVraylar | $638 | $69,96347 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $540 | $41,41519 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $439 | $37,32123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $343 | $21,31628 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $692 | $11,828142 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $65 | $5,70012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Zephyrhills
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.